CTCBIO Inc.
Financials
Valuation Metrics
CTCBIO Inc.'s Market Cap is ₩735B. At end of 2025 it was ₩1118B. Ranked #1450 of 2,436 in KR market (top 60%), #823 of 1,649 on KOSDAQ (top 50%), #160 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.51B KRW | KR#1,450/2,436 Sec#160/234 |
| Revenue | 124.11B KRW | KR#1,275/2,436 Sec#79/234 |
| Net Income | 6.11B KRW | KR#1,059/2,436 Sec#71/234 |
| Total Assets | 146.65B KRW | KR#1,489/2,436 Sec#116/234 |
| Net Assets | 76.22B KRW | KR#1,590/2,436 Sec#133/234 |
| Employees | 257 | KR#903/2,436 Sec#76/234 |
| Value | ||
| P/E | 12.04x | KR#826/2,436 Sec#50/234 |
| P/B | 0.96x | KR#1,457/2,436 Sec#94/234 |
| PEG | 0.03x | KR#173/2,436 Sec#7/234 |
| P/S | 0.59x | KR#1,049/2,436 Sec#46/234 |
| EV/EBITDA | 9.16x | KR#550/2,436 Sec#24/234 |
| FCF Yield | 4.89% | KR#873/2,436 Sec#45/234 |
| Profitability | ||
| ROE | 8.01% | KR#695/2,436 Sec#43/234 |
| ROA | 4.16% | KR#762/2,436 Sec#65/234 |
| Op. Margin | 8.00% | KR#620/2,436 Sec#55/234 |
| Revenue Growth | 1.00% | KR#1,376/2,436 Sec#129/234 |
| Earnings Growth | 451.04% | KR#118/2,436 Sec#7/234 |
| Financial Health | ||
| Debt Ratio | 192.40% | KR#1,650/2,436 Sec#187/234 |
| Total Debt | 35.70B KRW | KR#1,114/2,436 Sec#84/234 |
| FCF | 3.60B KRW | KR#984/2,436 Sec#70/234 |
| Cash | 18.20B KRW | KR#1,297/2,436 Sec#99/234 |
| Current Ratio | 1.47x | KR#1,325/2,436 Sec#145/234 |
| Net Debt/EBITDA | 1.76x | KR#870/2,436 Sec#62/234 |
| Performance | ||
| 1Y Return | -49.83% | KR#2,071/2,436 Sec#196/234 |
| 1M Return | -1.14% | KR#1,011/2,436 Sec#95/234 |
| From 52W High | -60.42% | KR#1,728/2,436 Sec#145/234 |
| 1Y MDD | -63.76% | KR#1,627/2,436 Sec#133/234 |
| Trading | ||
| Volume | 27,910 shares | KR#1,687/2,436 Sec#169/234 |
| Foreign Own. | 2.26% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 252 KRW | KR#1,144/2,436 Sec#80/234 |
| BPS | 3,188 KRW | KR#1,778/2,436 Sec#137/234 |
Company Info
CTC BIO, established in 1995 and headquartered in Hwaseong-si, Gyeonggi-do, listed on KOSDAQ in 2002. The company researches, develops, manufactures, and distributes animal pharmaceuticals, including feed additives, injectables, and vaccines, as well as improved new drugs and generic drugs. CTC BIO possesses 5 domestic production bases, 2 research institutes, and operates local subsidiaries in the USA and Indonesia, expanding its production base by acquiring the Ansan factory from SK Chemicals in 2014. Its technological prowess is recognized through core technologies such as microbial fermentation and drug coating, alongside the development of innovative film-type and complex formulations.